Pyzchiva 45 mg Ustekinumab Biosimilar Pre-filled Syringe

Pyzchiva 45 mg (Ustekinumab Biosimilar) Pre-filled Syringe — Complete Guide for Psoriasis and Inflammatory Bowel Disease

Key Facts Table

Short Description

Pyzchiva is a biosimilar version of ustekinumab that blocks IL-12 and IL-23, two cytokines central to the inflammation behind psoriasis, psoriatic arthritis, and inflammatory bowel disease. It offers the same clinical benefit as the reference biologic, confirmed through extensive comparability studies, with a notably infrequent every-12-week maintenance schedule.

Table of Contents

• Introduction
• What Is Pyzchiva?
• How Does It Work?
• Main Benefits
• Real Use Cases
• Who Is It Best For?
• Who Should Avoid It?
• How to Use Correctly
• Best Time to Use
• Common Questions Users Ask
• Expected Results Timeline
• Common Mistakes
• Myths vs Facts
• Drug Interactions
• Contraindications
• Required Tests
• What to Eat With It
• Effect on Other Medications
• When To See a Doctor
• NSL Expert Tip
• Conversational FAQ
• Conclusion

Introduction

Ustekinumab was a landmark biologic when introduced, targeting IL-12 and IL-23 rather than the more commonly blocked TNF-alpha pathway, and it remains a mainstay across psoriasis, psoriatic arthritis, and inflammatory bowel disease. Pyzchiva brings this well-established therapy to more patients as a biosimilar, backed by phase III comparability data showing equivalent skin-clearance outcomes to the reference product.

What Is Pyzchiva?

Pyzchiva is a biosimilar medicinal product containing ustekinumab, a human monoclonal antibody. It is approved for adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately-to-severely active Crohn’s disease, and moderately-to-severely active ulcerative colitis, as well as children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis.

How Does It Work?

Ustekinumab binds to the shared p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), preventing these cytokines from binding to their receptors on immune cells. Both IL-12 and IL-23 play a role in activating T cells that drive inflammation in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Blocking both simultaneously interrupts this inflammatory signaling, reducing skin plaques, joint symptoms, and intestinal inflammation.

Main Benefits

• Same proven mechanism and efficacy as originator ustekinumab, confirmed through biosimilarity studies (comparable PASI score improvements).
• Notably infrequent maintenance dosing — every 12 weeks for psoriasis and psoriatic arthritis after the starting doses.
• Approved across a wide range of conditions: skin, joints, and inflammatory bowel disease.
• Pediatric indication available for plaque psoriasis and psoriatic arthritis (6 years and older).
• Weight-based dosing options ensure appropriate coverage for larger body weights.
• Self-injectable at home after training, using a pre-filled syringe or autoinjector.

Real Use Cases

• An adult with moderate-to-severe plaque psoriasis seeking a therapy with infrequent dosing.
• A psoriatic arthritis patient needing systemic biologic control of joint and skin symptoms.
• A Crohn’s disease or ulcerative colitis patient with inadequate response to conventional therapy.
• A child or adolescent (6+) with moderate-to-severe plaque psoriasis or psoriatic arthritis.

Who Is It Best For?

Adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately-to-severely active Crohn’s disease, or ulcerative colitis, and children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, under specialist care (dermatology, rheumatology, or gastroenterology depending on indication).

Who Should Avoid It?

• Anyone with hypersensitivity to ustekinumab or excipients.
• Patients with clinically significant active infections until resolved.
• Patients with untreated latent tuberculosis until prophylaxis is initiated — TB screening is required before starting.
• Report any history of noninfectious pneumonia symptoms (interstitial, eosinophilic, or cryptogenic organizing pneumonia have been reported with ustekinumab products).
• Caution regarding live vaccines, which should be completed before starting treatment.

How to Use Correctly

1. Plaque psoriasis / psoriatic arthritis (≤100 kg): 45 mg subcutaneously at week 0, then again at week 4, then every 12 weeks.
2. Plaque psoriasis (>100 kg): 90 mg using the same schedule.
3. Crohn’s disease / ulcerative colitis: a weight-based intravenous induction dose, followed by 90 mg subcutaneously 8 weeks later, then every 8 weeks.
4. Pediatric dosing: weight-based at the initial dose, 4 weeks later, then every 12 weeks.
5. Inject into the thigh, abdomen, upper arm, or buttock; rotate sites and avoid psoriasis plaques or damaged skin.
6. Let the syringe reach room temperature before injecting, per the leaflet.

Best Time to Use

Follow the two starting doses precisely (week 0 and week 4), then settle into your maintenance interval (every 8 or 12 weeks depending on condition) on a fixed calendar date. Because the interval is long, marking future injection dates well in advance helps avoid missed doses.

Common Questions Users Ask

Why does dosing depend on body weight for psoriasis but not for IBD? Psoriasis and psoriatic arthritis dosing uses a fixed 45 mg or 90 mg based on a 100 kg weight threshold, while Crohn’s disease and ulcerative colitis induction dosing is calculated more precisely based on actual body weight.

Is a biosimilar as effective as ustekinumab? Yes — Pyzchiva’s phase III trial showed comparable improvement in psoriasis severity scores to the reference product, confirming biosimilarity.

How often will I need injections long-term? For psoriasis and psoriatic arthritis, typically every 12 weeks — one of the least frequent dosing schedules among biologics.

Expected Results Timeline

Common Mistakes

• Missing the second starting dose at week 4, which is essential for establishing full effect.
• Confusing the psoriasis/PsA dosing interval (every 12 weeks) with the IBD interval (every 8 weeks).
• Losing track of the long maintenance interval and missing scheduled doses.
• Assuming a biosimilar is less effective than the reference biologic despite equivalent trial data.
• Not completing TB screening or vaccinations before starting.

Myths vs Facts

Drug Interactions

• Live vaccines: avoid during treatment; complete vaccinations beforehand.
• Other biologics or strong immunosuppressants: combination is generally avoided due to increased infection risk.
• Report all medications to your specialist, particularly any other systemic therapies for the same condition.

Contraindications

Hypersensitivity to ustekinumab or any excipient. Clinically significant active infections should be resolved before starting, and untreated latent tuberculosis requires prophylaxis first.

Required Tests

• Tuberculosis screening before starting.
• Review and completion of age-appropriate vaccinations prior to treatment.
• Ongoing clinical assessment of skin, joint, or bowel symptom response.
• Monitoring for respiratory symptoms given reports of noninfectious pneumonia with ustekinumab products.

What to Eat With It

Pyzchiva has no specific food interactions. A balanced, anti-inflammatory-leaning diet — rich in vegetables, whole grains, omega-3 sources, and adequate protein — supports overall skin and joint health during treatment. Patients with Crohn’s disease or ulcerative colitis should follow specific dietary guidance from their gastroenterologist, since nutritional needs can differ significantly during flares versus remission.

Effect on Other Medications

As a biologic antibody, ustekinumab does not act through liver enzyme pathways the way small-molecule drugs typically do. The main practical considerations are vaccine timing and avoiding combination with other immunosuppressive biologics unless specifically directed by your specialist.

When To See a Doctor

• Signs of infection: persistent fever, cough, or any severe or unusual infection.
• New or worsening respiratory symptoms such as shortness of breath or persistent cough, given reports of noninfectious pneumonia.
• Allergic reaction symptoms: swelling, hives, difficulty breathing.
• No meaningful improvement by the expected assessment point (around week 12–16).
• Before any planned vaccination or surgery.

NSL Expert Tip

Conversational FAQ

Is Pyzchiva the same as Stelara?
Pyzchiva is a biosimilar to originator ustekinumab (Stelara), containing the same active substance with demonstrated equivalent efficacy and safety in regulatory trials.

How is my dose determined for psoriasis?
Body weight determines whether you receive 45 mg or 90 mg — patients over 100 kg typically receive the higher dose.

Can children use Pyzchiva?
Yes, it is approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis in children 6 years and older, with weight-based dosing.

Why is the IBD schedule different from the psoriasis schedule?
Crohn’s disease and ulcerative colitis begin with a weight-based intravenous induction dose, then switch to subcutaneous maintenance every 8 weeks, reflecting the specific dosing studied for these conditions.

Do I need TB screening?
Yes, tuberculosis screening is standard before starting Pyzchiva, as with other biologics targeting the immune system.

Conclusion

Pyzchiva 45 mg offers the well-established benefits of ustekinumab therapy — blocking both IL-12 and IL-23 across plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis — through a biosimilar with comparable efficacy confirmed in clinical trials. With correct condition-specific dosing, appropriate pre-treatment screening, and attention to the long maintenance interval, it provides a reliable and notably infrequent-dosing option across this range of inflammatory conditions. It remains a prescription-only biologic requiring specialist supervision.